Nemus Bioscience Stock Rises Above 50-Day Average

Shares of the Houston-based biotech company trading on the OTCMKTS exchange see a price spike.

Apr. 19, 2026 at 5:34pm

Got story updates? Submit your updates here. ›

A high-end studio photograph featuring a glass beaker, mortar and pestle, and green plant matter arranged elegantly on a clean white background, conceptually representing the research and development of cannabinoid-based pharmaceuticals.A photorealistic still life captures the tools of pharmaceutical research, hinting at the potential of Nemus Bioscience's cannabinoid-based drug pipeline.Houston Today

Shares of Nemus Bioscience Inc. (OTCMKTS:NMUS), an early-stage biopharmaceutical company developing cannabinoid-based therapeutics, rose above their 50-day moving average during trading on Friday. The stock closed at $0.72 with trading volume of 79,485 shares, giving the company a market cap of $105.64 million.

Why it matters

Nemus Bioscience is focused on developing synthetic cannabinoid-based treatments for ophthalmic, dermatological, and metabolic diseases. The company's stock price movement above its 50-day average could signal growing investor interest in the company's pipeline and potential future catalysts.

The details

Nemus Bioscience is an early-stage biotech company that is leveraging synthetic derivatives of naturally occurring cannabinoids to develop improved treatments for various medical conditions. The company's pipeline includes multiple preclinical candidates, with lead programs targeting ophthalmic and dermatological indications.

  • Nemus Bioscience shares crossed above their 50-day moving average during trading on Friday, April 19, 2026.

The players

Nemus Bioscience, Inc.

An early-stage biopharmaceutical company developing proprietary prodrug cannabinoid therapeutics for ophthalmic, dermatological and metabolic diseases. The company is headquartered in Houston, Texas and trades on the OTCMKTS exchange.

Got photos? Submit your photos here. ›

The takeaway

Nemus Bioscience's stock price movement above its 50-day average suggests growing investor interest in the company's cannabinoid-based drug pipeline, which is focused on developing treatments for various medical conditions including eye, skin, and metabolic disorders.